Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
follitropin delta
- Development stage
- Phase 4
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Follitropin delta is a recombinant human follicle-stimulating hormone (rFSH) produced in the human fetal retinal cell line PER.C6 using recombinant DNA technology. Developed by Ferring Pharmaceuticals, it is the first rFSH to be derived from a human cell line, which results in a glycosylation profile distinct from CHO-derived FSH (such as follitropin alfa or beta). Specifically, follitropin delta contains both α2,3- and α2,6-linked sialic acid, leading to a lower clearance rate and higher biopotency in humans. It is indicated for controlled ovarian stimulation in women undergoing assisted reproductive technology (ART) programs, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). The drug is typically administered using an individualized dosing algorithm based on a patient's body weight and serum anti-Müllerian hormone (AMH) levels to optimize the number of oocytes retrieved while reducing the risk of ovarian hyperstimulation syndrome (OHSS).
- Brand names
- Rekovelle
- Other names
- recombinant human follicle-stimulating hormonerhFSHrFSH
02
Targets
FSHR (Follicle-stimulating hormone receptor)
Beyond the preview
Go deeper on follitropin delta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on follitropin delta.